SynthesisPloS one2014
Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 6 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder.The Cochrane database of systematic reviews · 2021Pooled it
- Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis.Journal of anxiety disorders · 2019Pooled it
- A Meta-Analysis of D-Cycloserine in Exposure-Based Treatment: Moderators of Treatment Efficacy, Response, and Diagnostic Remission.The Journal of clinical psychiatry · 2017Pooled it
- D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis.PloS one · 2017Pooled it
- Harnessing reconsolidation to weaken fear and appetitive memories: A meta-analysis of post-retrieval extinction effects.Psychological bulletin · 2016Pooled it
- Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders.The Cochrane database of systematic reviews · 2015Pooled it
- Technology-enhanced in vivo exposures in Prolonged Exposure for PTSD: A pilot randomized controlled trial.Journal of psychiatric research · 2022Trial
- A randomized, placebo-controlled laboratory study of the effects of D-cycloserine on sexual memory consolidation in women.Psychopharmacology · 2020Trial
- Augmenting extinction learning with D-cycloserine reduces return of fear: a randomized, placebo-controlled fMRI study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- N-methyl-D-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents.Child psychiatry and human development · 2019Trial
- The NMDA receptor partial agonist d-cycloserine does not enhance motor learning.Journal of psychopharmacology (Oxford, England) · 2016Trial
- RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER.Depression and anxiety · 2016Trial
- Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy.Behaviour research and therapy · 2016Trial
- A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders.Molecular autism · 2016Trial
- Exercise Augmentation of Exposure Therapy for PTSD: Rationale and Pilot Efficacy Data.Cognitive behaviour therapy · 2015Trial
- A randomized trial of a digitally delivered, home-based neuromodulation and mindfulness intervention for pain management in older adults with knee osteoarthritis.NPJ digital medicine · 2026Article
- The amygdala NT3-TrkC pathway underlies inter-individual differences in fear extinction and related synaptic plasticity.Molecular psychiatry · 2024Article
- Virtual Reality exposure therapy in the treatment of public speaking anxiety and social anxiety disorder.Neuroscience applied · 2024Review
- Enhancing Fear Extinction: Pharmacological Approaches.Current topics in behavioral neurosciences · 2023Article
- Understanding Human Fear Extinction: Insights from Psychophysiology.Current topics in behavioral neurosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of anxiety is on the edge of a new era of combinations of pharmacologic and psychosocial interventions. A new wave of translational research has focused on the use of pharmacological agents as psychotherapy adjuvants using neurobiological insights into the mechanism of the action of certain psychological treatments such as exposure therapy. Recently, d-cycloserine (DCS) an antibiotic used to treat tuberculosis has been applied to enhance exposure-based treatment for anxiety and has proved to be a promising, but as yet unproven intervention. The present study aimed to evaluate the efficacy of DCS in the enhancement of exposure therapy in anxiety disorders. A systematic review/meta-analysis was conducted. Electronic searches were conducted in the databases ISI-Web of Science, Pubmed and PsycINFO. We included only randomized, double-blind, placebo-controlled trials with humans, focusing on the role of DCS in enhancing the action of exposure therapy for anxiety disorders. We identified 328 references, 13 studies were included in our final sample: 4 on obsessive-compulsive disorder, 2 on panic disorder, 2 on social anxiety disorder, 2 on posttraumatic stress disorder, one on acrophobia, and 2 on snake phobia. The results of the present meta-analysis show that DCS enhances exposure therapy in the treatment of anxiety disorders (Cohen d = -0.34; CI: -0.54 to -0.14), facilitating the specific process of extinction of fear. DCS seems to be effective when administered at a time close to the exposure therapy, at low doses and a limited number of times. DCS emerges as a potential new therapeutic approach for patients with refractory anxiety disorders that are unresponsive to the conventional treatments available. When administered correctly, DCS is a promising strategy for augmentation of CBT and could reduce health care costs, drop-out rates and bring faster relief to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.